Would you consider addition of adjuvant Capecitabine to TDM-1 in a patient with residual disease after neoadjuvant therapy (TCHP) for biopsy proven HR- HER2 positive breast cancer if residual disease after mastectomy shows HR- HER2 negative disease?
Would adding an oral agent like Capecitabine for the triple negative to T-DM1be advisable?
Community PollStarted
What adjuvant therapy would you offer a patient with HER2+ breast cancer with residual disease after neoadjuvant therapy if the residual disease is HER2 negative?
84 physicians have voted
Join Mednetto vote and see how they answered.